BARTALENA, LUIGI Statistiche
BARTALENA, LUIGI
Add-On Effect of Selenium and Vitamin D Combined Supplementation in Early Control of Graves’ Disease Hyperthyroidism During Methimazole Treatment
2022-01-01 Gallo, D.; Mortara, L.; Veronesi, G.; Cattaneo, S. A. M.; Genoni, A.; Gallazzi, M.; Peruzzo, C.; Lasalvia, P.; Moretto, P.; Bruno, A.; Passi, A.; Pini, A.; Nauti, A.; Lavizzari, M. A.; Marino, M.; Lanzolla, G.; Tanda, M. L.; Bartalena, L.; Piantanida, E.
Real-life data on the impact of medical therapy for amiodarone-induced thyrotoxicosis on CV events and hospitalizations
2022-01-01 Cappellani, Daniele; Marconcini, Giulia; Manetti, Luca; Bartalena, Luigi; Bogazzi, Fausto
Reply to Letter to the Editor by Dr. Terry J. Smith regarding teprotumumab and ototoxicity
2022-01-01 Bartalena, L.; Marcocci, C.; Tanda, M. L.; Marino, M.
Teprotumumab for Graves??? orbitopathy and ototoxicity: moving problems from eyes to ears?
2022-01-01 Bartalena, L.; Marin??, M.; Marcocci, C.; Tanda, M. L.
Identification of Two Different Phenotypes of Patients with Amiodarone-Induced Thyrotoxicosis and Positive Thyrotropin Receptor Antibody Tests
2021-01-01 Cappellani, Daniele; DE MARCO, Giuseppina; Ferrarini, Eleonora; Torregrossa, Liborio; DI CERTO, AGOSTINO MARIA; Cosentino, Giada; Urbani, Claudio; Marconcini, Giulia; Mattiello, Alessandro; Manetti, Luca; Agretti, Patrizia; Basolo, Fulvio; Tonacchera, Massimo; Bartalena, Luigi; Bogazzi, Fausto
Identification of Two Different Phenotypes of Patients with Amiodarone-Induced Thyrotoxicosis and Positive Thyrotropin Receptor Antibody Tests
2021-01-01 Cappellani, D.; De Marco, G.; Ferrarini, E.; Torregrossa, L.; Di Certo, A. M.; Cosentino, G.; Urbani, C.; Marconcini, G.; Mattiello, A.; Manetti, L.; Agretti, P.; Basolo, F.; Tonacchera, M.; Bartalena, L.; Bogazzi, F.
The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy
2021-01-01 Bartalena, L.; Kahaly, G. J.; Baldeschi, L.; Dayan, C. M.; Eckstein, A.; Marcocci, C.; Marino, M.; Vaidya, B.; Wiersinga, W. M.
Asymmetry indicates more severe and active disease in Graves’ orbitopathy: results from a prospective cross-sectional multicentre study
2020-01-01 Perros, P.; Zarkovic, M. P.; Panagiotou, G. C.; Azzolini, C.; Ayvaz, G.; Baldeschi, L.; Bartalena, L.; Boschi, A. M.; Nardi, M.; Brix, T. H.; Covelli, D.; Daumerie, C.; Eckstein, A. K.; Fichter, N.; Ciric, S.; Hegedus, L.; Kahaly, G. J.; Konuk, O.; Lareida, J. J.; Okosieme, O. E.; Leo, M.; Mathiopoulou, L.; Clarke, L.; Menconi, F.; Morris, D. S.; Orgiazzi, J.; Pitz, S.; Salvi, M.; Muller, I.; Knezevic, M.; Wiersinga, W. M.; Curro, N.; Dayan, C. M.; Marcocci, C.; Marino, M.; Moller, L.; Pearce, S. H.; Toruner, F.; Bernard, M.; Perros, P.; Lareida, J. J.
Duration of Exposure to Thyrotoxicosis Increases Mortality of Compromised AIT Patients: the Role of Early Thyroidectomy.
2020-01-01 Cappellani, D; Papini, P; DI CERTO, AGOSTINO MARIA; Morganti, R; Urbani, C; Manetti, L; Tanda, Ml; Cosentino, G; Marconcini, G; Materazzi, G; Martino, E; Bartalena, L; Bogazzi, F.
Management of Graves’ hyperthyroidism and orbitopathy in time of COVID-19 pandemic
2020-01-01 Bartalena, L.; Chiovato, L.; Marcocci, C.; Vitti, P.; Piantanida, E.; Tanda, M. L.
2018 European Thyroid Association (ETA) guidelines for the management of amiodarone-associated thyroid dysfunction
2018-01-01 Bartalena, L.; Bogazzi, F.; Chiovato, L.; Hubalewska-Dydejczyk, A.; Links, T. P.; Vanderpump, M.
Combined mycophenolate + prednisolone therapy is more effective than prednisolone in active and moderate-to-severe Graves’ Orbitopathy – A randomized, observer blind, multicenter trial
2018-01-01 Kahaly, Gj; Riedl, M; König, J; Pitz, S; Kampmann, E; Kolbe, E; Ponto, Ka; Diana, T; Eckstein, A; Müller, L; Führer, D; Salvi, M; Campi, I; Covelli, D; Curro, N; Leo, M; Marinò, M; Menconi, F; Marcocci, C; Bartalena, L; Perros, P; Wiersinga, Wm
Selenium in the Treatment of Thyroid Diseases
2017-01-01 Marino', Michele; Marcocci, Claudio; Vitti, Paolo; Chiovato, Luca; Bartalena, Luigi
Effects of treatment modalities for Graves' hyperthyroidism on Graves' orbitopathy: A 2015 Italian Society of Endocrinology Consensus Statement
2015-01-01 Bartalena, Luigi; Macchia, P. E.; Marcocci, Claudio; Salvi, M.; Vermiglio, F.
Effects of Amiodarone, Thyroid Hormones and CYP2C9 and VKORC1 Polymorphisms on Warfarin Metabolism: A Review of the Literature.
2013-01-01 Tomisti, L; Del Re, M; Bartalena, L; Tanda, Ml; Pucci, A; Pambianco, F; Danesi, R; Braverman, Le; Martino, E; Bogazzi, F.
REGULATION OF CARDIAC FATTY ACID METABOLISM IN TRANSGENIC MICE OVEREXPRESSING BOVINE GROWTH HORMONE
2009-01-01 Bogazzi, Fausto; Raggi, Francesco; Ultimieri, Federica; Russo, Dania; D'Alessio, Aldo; Manariti, Antonella; Sandra, Brogioni; Bartalena, Luigi; Martino, Enio
Cardiac expression of adenine nucleotide translocase-1 in transgenic mice overexpressing bovine GH
2007-01-01 Bogazzi, Fausto; Raggi, Francesco; Ultimieri, Federica; Russo, Dania; Manariti, Antonella; D'Alessio, Aldo; Viacava, Paolo; Fanelli, Giovanni; Gasperi, Maurizio; Bartalena, Luigi; Martino, Enio
Autoimmune hepatitis during intravenous glucocorticoid pulse therapy for Graves' ophthalmopathy treated successfully with glucocorticoids themselves
2005-01-01 Marcocci, C; Pincheral, A; Bartalena, L; Vitti, P; Campani, D; Pollina, Le; Brunetto, Mr; Oliveri, F; Ambrogini, E; Altea, Ma; Morabito, E; Marinò, M.
Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves' ophthalmopathy
2004-01-01 Marocci, C; Pinchera, A; Bartalena, L; Brunetto, Mr; Morabito, Evangelia; Marinó, M.
Mutations in the SLC26A4 (pendrin) gene in patients with sensorineural deafness and enlarged vestibular aqueduct
2004-01-01 Bogazzi, F.; Russo, D.; Raggi, F.; Ultimieri, F.; Berrettini, S.; Forli, F.; Grasso, L.; Ceccarelli, C.; Mariotti, S.; Pinchera, A.; Bartalena, L.; Martino, E.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Add-On Effect of Selenium and Vitamin D Combined Supplementation in Early Control of Graves’ Disease Hyperthyroidism During Methimazole Treatment | 1-gen-2022 | Gallo, D.; Mortara, L.; Veronesi, G.; Cattaneo, S. A. M.; Genoni, A.; Gallazzi, M.; Peruzzo, C.; Lasalvia, P.; Moretto, P.; Bruno, A.; Passi, A.; Pini, A.; Nauti, A.; Lavizzari, M. A.; Marino, M.; Lanzolla, G.; Tanda, M. L.; Bartalena, L.; Piantanida, E. | |
| Real-life data on the impact of medical therapy for amiodarone-induced thyrotoxicosis on CV events and hospitalizations | 1-gen-2022 | Cappellani, Daniele; Marconcini, Giulia; Manetti, Luca; Bartalena, Luigi; Bogazzi, Fausto | |
| Reply to Letter to the Editor by Dr. Terry J. Smith regarding teprotumumab and ototoxicity | 1-gen-2022 | Bartalena, L.; Marcocci, C.; Tanda, M. L.; Marino, M. | |
| Teprotumumab for Graves??? orbitopathy and ototoxicity: moving problems from eyes to ears? | 1-gen-2022 | Bartalena, L.; Marin??, M.; Marcocci, C.; Tanda, M. L. | |
| Identification of Two Different Phenotypes of Patients with Amiodarone-Induced Thyrotoxicosis and Positive Thyrotropin Receptor Antibody Tests | 1-gen-2021 | Cappellani, Daniele; DE MARCO, Giuseppina; Ferrarini, Eleonora; Torregrossa, Liborio; DI CERTO, AGOSTINO MARIA; Cosentino, Giada; Urbani, Claudio; Marconcini, Giulia; Mattiello, Alessandro; Manetti, Luca; Agretti, Patrizia; Basolo, Fulvio; Tonacchera, Massimo; Bartalena, Luigi; Bogazzi, Fausto | |
| Identification of Two Different Phenotypes of Patients with Amiodarone-Induced Thyrotoxicosis and Positive Thyrotropin Receptor Antibody Tests | 1-gen-2021 | Cappellani, D.; De Marco, G.; Ferrarini, E.; Torregrossa, L.; Di Certo, A. M.; Cosentino, G.; Urbani, C.; Marconcini, G.; Mattiello, A.; Manetti, L.; Agretti, P.; Basolo, F.; Tonacchera, M.; Bartalena, L.; Bogazzi, F. | |
| The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy | 1-gen-2021 | Bartalena, L.; Kahaly, G. J.; Baldeschi, L.; Dayan, C. M.; Eckstein, A.; Marcocci, C.; Marino, M.; Vaidya, B.; Wiersinga, W. M. | |
| Asymmetry indicates more severe and active disease in Graves’ orbitopathy: results from a prospective cross-sectional multicentre study | 1-gen-2020 | Perros, P.; Zarkovic, M. P.; Panagiotou, G. C.; Azzolini, C.; Ayvaz, G.; Baldeschi, L.; Bartalena, L.; Boschi, A. M.; Nardi, M.; Brix, T. H.; Covelli, D.; Daumerie, C.; Eckstein, A. K.; Fichter, N.; Ciric, S.; Hegedus, L.; Kahaly, G. J.; Konuk, O.; Lareida, J. J.; Okosieme, O. E.; Leo, M.; Mathiopoulou, L.; Clarke, L.; Menconi, F.; Morris, D. S.; Orgiazzi, J.; Pitz, S.; Salvi, M.; Muller, I.; Knezevic, M.; Wiersinga, W. M.; Curro, N.; Dayan, C. M.; Marcocci, C.; Marino, M.; Moller, L.; Pearce, S. H.; Toruner, F.; Bernard, M.; Perros, P.; Lareida, J. J. | |
| Duration of Exposure to Thyrotoxicosis Increases Mortality of Compromised AIT Patients: the Role of Early Thyroidectomy. | 1-gen-2020 | Cappellani, D; Papini, P; DI CERTO, AGOSTINO MARIA; Morganti, R; Urbani, C; Manetti, L; Tanda, Ml; Cosentino, G; Marconcini, G; Materazzi, G; Martino, E; Bartalena, L; Bogazzi, F. | |
| Management of Graves’ hyperthyroidism and orbitopathy in time of COVID-19 pandemic | 1-gen-2020 | Bartalena, L.; Chiovato, L.; Marcocci, C.; Vitti, P.; Piantanida, E.; Tanda, M. L. | |
| 2018 European Thyroid Association (ETA) guidelines for the management of amiodarone-associated thyroid dysfunction | 1-gen-2018 | Bartalena, L.; Bogazzi, F.; Chiovato, L.; Hubalewska-Dydejczyk, A.; Links, T. P.; Vanderpump, M. | |
| Combined mycophenolate + prednisolone therapy is more effective than prednisolone in active and moderate-to-severe Graves’ Orbitopathy – A randomized, observer blind, multicenter trial | 1-gen-2018 | Kahaly, Gj; Riedl, M; König, J; Pitz, S; Kampmann, E; Kolbe, E; Ponto, Ka; Diana, T; Eckstein, A; Müller, L; Führer, D; Salvi, M; Campi, I; Covelli, D; Curro, N; Leo, M; Marinò, M; Menconi, F; Marcocci, C; Bartalena, L; Perros, P; Wiersinga, Wm | |
| Selenium in the Treatment of Thyroid Diseases | 1-gen-2017 | Marino', Michele; Marcocci, Claudio; Vitti, Paolo; Chiovato, Luca; Bartalena, Luigi | |
| Effects of treatment modalities for Graves' hyperthyroidism on Graves' orbitopathy: A 2015 Italian Society of Endocrinology Consensus Statement | 1-gen-2015 | Bartalena, Luigi; Macchia, P. E.; Marcocci, Claudio; Salvi, M.; Vermiglio, F. | |
| Effects of Amiodarone, Thyroid Hormones and CYP2C9 and VKORC1 Polymorphisms on Warfarin Metabolism: A Review of the Literature. | 1-gen-2013 | Tomisti, L; Del Re, M; Bartalena, L; Tanda, Ml; Pucci, A; Pambianco, F; Danesi, R; Braverman, Le; Martino, E; Bogazzi, F. | |
| REGULATION OF CARDIAC FATTY ACID METABOLISM IN TRANSGENIC MICE OVEREXPRESSING BOVINE GROWTH HORMONE | 1-gen-2009 | Bogazzi, Fausto; Raggi, Francesco; Ultimieri, Federica; Russo, Dania; D'Alessio, Aldo; Manariti, Antonella; Sandra, Brogioni; Bartalena, Luigi; Martino, Enio | |
| Cardiac expression of adenine nucleotide translocase-1 in transgenic mice overexpressing bovine GH | 1-gen-2007 | Bogazzi, Fausto; Raggi, Francesco; Ultimieri, Federica; Russo, Dania; Manariti, Antonella; D'Alessio, Aldo; Viacava, Paolo; Fanelli, Giovanni; Gasperi, Maurizio; Bartalena, Luigi; Martino, Enio | |
| Autoimmune hepatitis during intravenous glucocorticoid pulse therapy for Graves' ophthalmopathy treated successfully with glucocorticoids themselves | 1-gen-2005 | Marcocci, C; Pincheral, A; Bartalena, L; Vitti, P; Campani, D; Pollina, Le; Brunetto, Mr; Oliveri, F; Ambrogini, E; Altea, Ma; Morabito, E; Marinò, M. | |
| Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves' ophthalmopathy | 1-gen-2004 | Marocci, C; Pinchera, A; Bartalena, L; Brunetto, Mr; Morabito, Evangelia; Marinó, M. | |
| Mutations in the SLC26A4 (pendrin) gene in patients with sensorineural deafness and enlarged vestibular aqueduct | 1-gen-2004 | Bogazzi, F.; Russo, D.; Raggi, F.; Ultimieri, F.; Berrettini, S.; Forli, F.; Grasso, L.; Ceccarelli, C.; Mariotti, S.; Pinchera, A.; Bartalena, L.; Martino, E. |